Exchange: NYSE
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:01 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
5,957,400 | 5,443,300 | 5,600,700 | 5,602,000 | 6,046,600 |
Cost of Goods Sold (COGS) incl. D&A |
1,248,300 | 1,203,600 | 1,146,700 | 1,197,900 | 1,321,700 |
COGS excluding D&A |
903,700 | 833,900 | 784,700 | 812,000 | 1,002,800 |
Depreciation & Amortization Expense |
344,600 | 369,700 | 362,000 | 385,900 | 318,900 |
Gross Income |
4,709,100 | 4,239,700 | 4,454,000 | 4,404,100 | 4,724,900 |
SG&A Expense |
3,440,600 | 3,100,200 | 3,251,800 | 2,999,000 | 3,488,700 |
Research & Development |
1,463,100 | 1,342,800 | 1,320,700 | 1,151,500 | 1,355,300 |
Other SG&A |
1,977,500 | 1,757,400 | 1,931,100 | 1,847,500 | 2,133,400 |
Other Operating Expense |
0 | 0 | 0 | 0 | -71,800 |
Unusual Expense |
204,000 | 53,300 | 0 | 23,800 | 168,700 |
Non Operating Income/Expense |
-35,500 | 809,800 | -700 | -26,800 | -47,400 |
Equity in Affiliates (Pretax) |
NA | NA | 0 | 0 | 0 |
Interest Expense |
42,500 | 47,000 | 43,000 | 45,300 | 50,100 |
Gross Interest Expense |
47,700 | 47,000 | 43,000 | 45,300 | 50,100 |
Pretax Income |
1,012,500 | 1,874,700 | 1,185,700 | 1,335,300 | 1,041,800 |
Income Tax |
185,200 | 548,100 | 262,100 | 324,200 | 183,600 |
Equity in Affiliates |
0 | 0 | 0 | 0 | 0 |
Consolidated Net Income |
827,300 | 1,326,600 | 923,600 | 1,011,100 | 858,200 |
Minority Interest Expense |
0 | 0 | 0 | 0 | 0 |
Net Income |
827,300 | 1,326,600 | 923,600 | 1,011,100 | 858,200 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Net Income After Extraordinaries |
827,299 | 1,326,599 | 923,600 | 1,011,100 | 858,200 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
827,300 | 1,326,600 | 923,600 | 1,011,100 | 858,200 |
Operational EPS |
0.87 | 1.22 | 0.83 | 0.92 | 0.88 |
EPS (basic) |
0.75 | 1.18 | 0.83 | 0.91 | 0.77 |
EBITDA |
1,613,100 | 1,509,200 | 1,564,200 | 1,791,000 | 1,626,900 |
Depreciation & Amortization Expense |
344,600 | 369,700 | 362,000 | 385,900 | 318,900 |
Common Shares Outstanding |
1,117,972 | 1,119,600 | 1,118,700 | 1,117,000 | 1,113,967 |
Basic Shares Outstanding |
1,113,178 | 1,119,600 | 1,118,700 | 1,117,000 | 1,113,923 |
Diluted Shares Outstanding |
1,117,972 | 1,119,600 | 1,118,700 | 1,117,000 | 1,113,967 |
Diluted EPS after Extraordinary Items |
0.74 | 1.18 | 0.83 | 0.91 | 0.77 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
0.74 | 1.18 | 0.83 | 0.91 | 0.77 |
*Figures in thousands of U.S. Dollars except shares outstanding.
